Pfizer to end licence deal with Syros for blood disorder therapies
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
SYROS Pharmaceuticals said on Friday (Jul 22) Pfizer will terminate a licence deal between the companies related to the development of novel therapies for two blood disorders.
Shares of Syros were down 5.7 per cent in trading after the bell.
The termination will end the company’s more than three-year long collaboration with sickle cell disease drugmaker Global Blood Therapeutics (GBT) that Pfizer bought in a US$5.4 billion deal last August.
The partnership for sickle cell disease and beta thalassemia - diseases that affect the production and nature of hemoglobin in the blood is set to end on Oct 16, the company said.
Syros “intends to seek to identify a new out-licensing partner for its sickle cell disease program,” it added. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
